Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251508 · ClinicalTrials.gov registry record · Phase 1
Salvage Peanut Oral Immunotherapy Study
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03251508 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 15 participants.
The verdict
NCT03251508, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this trial is to study the safety of rescue peanut oral immunotherapy followed by the introduction of dietary peanut for patients with peanut allergy who have lost desensitization during a peanut immunotherapy trial.
Interventions
- DRUG Peanut OIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2018-01-03 |
| Est. Completion | 2021-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03251508
The ClinicalTrials.gov registry entry for NCT03251508 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peanut OIT is the first listed.
NCT03251508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03251508 about?
NCT03251508 is a clinical study titled "Salvage Peanut Oral Immunotherapy Study". The purpose of this trial is to study the safety of rescue peanut oral immunotherapy followed by the introduction of dietary peanut for patients with peanut allergy who have lost desensitization during a peanut immunotherapy trial.
What is the current status of trial NCT03251508?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2018-01-03. Estimated completion is 2021-11-23.
What interventions are being tested in trial NCT03251508?
The interventions under investigation include: Peanut OIT (DRUG).
Who is sponsoring clinical trial NCT03251508?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.